Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/55341
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChen, Chen-
dc.contributor.authorLu, Ye-
dc.date.accessioned2020-09-26T07:35:07Z-
dc.date.available2020-09-26T07:35:07Z-
dc.date.issued2020-09-
dc.identifier.issn0975-0975(Online); 0376-4710(Print)-
dc.identifier.urihttp://nopr.niscair.res.in/handle/123456789/55341-
dc.description1354-1358en_US
dc.description.abstractFour tetrandrine (TET) derivatives (IVa-IVd) have been synthesized by Suzuki reaction of boronic acid derivatives and 5-bromo-tetrandrine obtained by bromination using tetrandrine as the starting material. The structures are analyzed by 1H NMR, 13C NMR and ESI-MS. The inhibition activities of IVa-IVd against HL60 and A549 cancer cell lines have been investigated by CCK-8 assay. The compounds having significant (P <0.040) inhibition activities are secondarily screened by MTT assay. The inhibitory activities of IVa-IVd against protein tyrosine kinases (PTKs) are tested by ELISA. The results show that IVa, IVb and IVc exhibit significant inhibition activities against the two cancer cell lines. The IVb and IVc show highly significant (P <0.001) inhibition activities against fibroblast growth factor receptor 1 (FGFR1).en_US
dc.language.isoen_USen_US
dc.rights CC Attribution-Noncommercial-No Derivative Works 2.5 Indiaen_US
dc.sourceIJC-A Vol.59A(09) [September 2020]en_US
dc.subjectAnticanceren_US
dc.subjectBrominationen_US
dc.subjectCCK-8en_US
dc.subjectFGFR1en_US
dc.subjectPTKsen_US
dc.subjectSuzuki reactionen_US
dc.subjectTetrandrineen_US
dc.titleTetrandrine derivatives IVa-IVd: Structural analysis and their inhibition rate against protein tyrosine kinase, and HL60 & A549 cancer cell linesen_US
dc.typeArticleen_US
Appears in Collections:IJC-A Vol.59A(09) [September 2020]

Files in This Item:
File Description SizeFormat 
IJCA 59A(9) 1354-1358.pdf474.3 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.